These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36136040)

  • 1. Purely Predicting the Pharmaceutical Solubility: What to Expect from PC-SAFT and COSMO-RS?
    Klajmon M
    Mol Pharm; 2022 Nov; 19(11):4212-4232. PubMed ID: 36136040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Pure Predictions of Activity Coefficients from PC-SAFT Assist Drug-Polymer Compatibility Screening?
    Pavliš J; Mathers A; Fulem M; Klajmon M
    Mol Pharm; 2023 Aug; 20(8):3960-3974. PubMed ID: 37386723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the Thermodynamics of Ionic Liquids: What to Expect from PC-SAFT and COSMO-RS?
    Jiřiště L; Klajmon M
    J Phys Chem B; 2022 May; 126(20):3717-3736. PubMed ID: 35561456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of PC-SAFT EOS for Pharmaceuticals: Solubility, Co-Crystal, and Thermodynamic Modeling.
    Mahmoudabadi SZ; Pazuki G
    J Pharm Sci; 2021 Jun; 110(6):2442-2451. PubMed ID: 33412168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering.
    Loschen C; Klamt A
    J Pharm Pharmacol; 2015 Jun; 67(6):803-11. PubMed ID: 25851032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailor-made solvents for pharmaceutical use? Experimental and computational approach for determining solubility in deep eutectic solvents (DES).
    Palmelund H; Andersson MP; Asgreen CJ; Boyd BJ; Rantanen J; Löbmann K
    Int J Pharm X; 2019 Dec; 1():100034. PubMed ID: 31993583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
    Paus R; Ji Y; Vahle L; Sadowski G
    Mol Pharm; 2015 Aug; 12(8):2823-33. PubMed ID: 26107071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive PC-SAFT EOS based on COSMO for pharmaceutical compounds.
    Mahmoudabadi SZ; Pazuki G
    Sci Rep; 2021 Mar; 11(1):6405. PubMed ID: 33742065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-polymer compatibility prediction via COSMO-RS.
    Mathers A; Fulem M
    Int J Pharm; 2024 Oct; 664():124613. PubMed ID: 39179010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-Liquid Equilibrium in Co-Amorphous Systems: Experiment and Prediction.
    Zemánková A; Hassouna F; Klajmon M; Fulem M
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Solvation Free Energies from the Minnesota Solvation Database Using Classical Density Functional Theory Based on the PC-SAFT Equation of State.
    Bursik B; Eller J; Gross J
    J Phys Chem B; 2024 Apr; 128(15):3677-3688. PubMed ID: 38579126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extremely Low Vapor-Pressure Data as Access to PC-SAFT Parameter Estimation for Ionic Liquids and Modeling of Precursor Solubility in Ionic Liquids.
    Bülow M; Greive M; Zaitsau DH; Verevkin SP; Held C
    ChemistryOpen; 2021 Feb; 10(2):216-226. PubMed ID: 33492786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental and model-based approach to evaluate solvent effects on the solubility of the pharmaceutical artemisinin.
    Wünsche S; Tenberg V; Oliynyk K; Seidel-Morgenstern A; Lorenz H; Sadeghi M
    Eur J Pharm Sci; 2024 Sep; 200():106826. PubMed ID: 38866112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design.
    Ruether F; Sadowski G
    J Pharm Sci; 2009 Nov; 98(11):4205-15. PubMed ID: 19283772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermodynamic phase behavior of API/polymer solid dispersions.
    Prudic A; Ji Y; Sadowski G
    Mol Pharm; 2014 Jul; 11(7):2294-304. PubMed ID: 24870944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COSMOPharm: Drug-Polymer Compatibility of Pharmaceutical Amorphous Solid Dispersions from COSMO-SAC.
    Antolović I; Vrabec J; Klajmon M
    Mol Pharm; 2024 Sep; 21(9):4395-4415. PubMed ID: 39078049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Jan; 14(1):157-171. PubMed ID: 28043133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Low-Molecular-Weight Excipients on the Phase Behavior of PVPVA64 Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
    Pharm Res; 2018 Jan; 35(1):25. PubMed ID: 29305717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical stability of hydroxypropyl methylcellulose-based amorphous solid dispersions: Experimental and computational study.
    Iemtsev A; Hassouna F; Mathers A; Klajmon M; Dendisová M; Malinová L; Školáková T; Fulem M
    Int J Pharm; 2020 Nov; 589():119845. PubMed ID: 32931845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation.
    Abramov YA; Loschen C; Klamt A
    J Pharm Sci; 2012 Oct; 101(10):3687-97. PubMed ID: 22821740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.